Study:
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Rationale:
Drugs used in chemotherapy work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more tumor cells. Isotretinoin may help
chemotherapy work better by making tumor cells more sensitive to the drugs. Radiation
therapy uses high-energy x-rays to kill tumor cells. Carboplatin may make tumor cells more
sensitive to radiation therapy. It is not yet known which chemotherapy and radiation therapy
regimen is more effective in treating brain tumors.
Purpose:
This randomized phase III trial is studying different chemotherapy and radiation
therapy regimens to compare how well they work in treating young patients with newly
diagnosed, previously untreated, high-risk medulloblastoma or supratentorial primitive
neuroectodermal tumor.
Study Status: Recruiting
Recruiting:
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100
| Condition |
Intervention |
Phase |
|
Brain and Central Nervous System Tumors |
Biological: filgrastim
Drug: carboplatin
Drug: cisplatin
Drug: cyclophosphamide
Drug: isotretinoin
Drug: vincristine sulfate
Radiation: radiation therapy |
Phase 3 |
Verified by
Children`s Oncology Group
November, 2012
Sponsored by: Children`s Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00392327
Study Type: Interventional
Study Design: Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
James Olson, MD, PhD., Study Chair
Roger J. Packer, MD.,